Kiniksa Pharmaceuticals International, plc Class A
As of Oct 22, 2026, Kiniksa Pharmaceuticals International is in Stage 2, the uptrend phase, now in week 73 (since May 15, 2025). It closed at $80.79, 2.9% below its 52-week high and above its 200-day average, which is rising.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care
Is KNSA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
KNSA among Drug Manufacturers - Specialty & Generic7th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
Kiniksa Pharmaceuticals International: quick answers
What stage is Kiniksa Pharmaceuticals International in?
As of Oct 22, 2026, Kiniksa Pharmaceuticals International (KNSA) is in Stage 2, the uptrend phase. It entered Stage 2 on May 15, 2025 and is in week 73. What the four stages mean
Is Kiniksa Pharmaceuticals International in an uptrend?
Yes. Kiniksa Pharmaceuticals International is in a Stage 2 uptrend. It trades 37.4% above its 200-day average, which is rising.
How far is Kiniksa Pharmaceuticals International from its 52-week high?
Kiniksa Pharmaceuticals International closed at $80.79 on Oct 22, 2026, 2.9% below its 52-week high of $83.17. Its 52-week low is $37.01.
How has Kiniksa Pharmaceuticals International performed over the past year?
As of Oct 22, 2026, Kiniksa Pharmaceuticals International is up 108.0% over the past year and up 92.3% so far in 2026.
Which sector and industry is Kiniksa Pharmaceuticals International in?
Kiniksa Pharmaceuticals International is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.